METiS TechBio Grants Global License for AI Designed T Cell Engager to Boulevard Bio

July 06, 2026
METiS TechBio has entered a global licensing agreement with Boulevard Bio, granting exclusive rights to develop, manufacture, and commercialize MTS-128, an AI designed trispecific T cell engager. The deal includes $20 million upfront and up to $1.6 billion in potential milestone payments.

METiS TechBio has entered an exclusive global licensing agreement with Boulevard Bio, granting Boulevard worldwide rights to develop, manufacture, and commercialize MTS-128, a trispecific T cell engager program. The arrangement was announced in a press release.

Under the terms of the agreement, METiS TechBio will receive a 20 million dollar upfront payment and may earn up to 1.6 billion dollars in development, regulatory, and commercial milestone payments. The company will also receive tiered royalties on sales of any resulting products.

MTS-128 was created using METiS TechBio's NanoForge platform, which integrates protein design, drug delivery system engineering, and therapeutic optimization through artificial intelligence. The program is intended to improve target cell killing efficiency and reduce off-target toxicity compared with conventional bispecific T cell engagers.

Founded by a team of MIT-trained scientists, METiS TechBio focuses on AI enabled drug delivery technologies, while Boulevard Bio is supported by Deerfield Management, a healthcare investment firm. METiS noted that the agreement reflects its transition from technology validation toward global commercialization of AI based therapeutic assets.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Enterprise AI Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Enterprise

07/06
Orqa and Remote Robotic Systems Sign $150M Deal to Expand Drone and AI Production in Canada
07/06
Sabanto and Verdant Robotics Integrate Autonomous Tractor and Precision Application Systems
07/06
HiLabs and Harvard Researchers Partner to Study Ghost Networks in Medicare Advantage
07/06
InterVenn and Aranscia Expand Partnership for GlycoKnow Ovarian Cancer Test
07/06
SK Telecom Plans 15GW AI Data Center Program to Establish Korea as Regional Hub

More from: Life Sciences

07/06
Marley Health Launches Clinical Intelligence Platform for Veterinary Care
07/06
CollPlant Biotechnologies Announces $2.6 Million Private Placement
07/06
HiLabs and Harvard Researchers Partner to Study Ghost Networks in Medicare Advantage
07/06
InterVenn and Aranscia Expand Partnership for GlycoKnow Ovarian Cancer Test
07/06
MGI Tech and Shanghai AI Lab Introduce Physical AI Systems for Life Sciences

Subscribe to Enterprise AI Brief

Weekly report on AI business applications, enterprise software releases, automation tools, and industry implementations.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like